Ourmeta-analysisincludedthreeRCTsan

Ourmeta-analysisincludedthreeRCTsandtwocomparativecontrol
studies involving 184 patients. There were 89 patients in the ritux-
imab arm and 95 patients in the control arm. Our results indicated
thatrituximabtreatmentcouldsignificantlyimprovetherelapse-free
survival rate in patients with NS compared with control therapy.
Moreover, rituximab treatment seemed to achieve ahigher complete
remission rate (39.62% for rituximab versus 25.45% for the control).
Furthermore, rituximab treatment significantly reduced the incid-
ence of proteinuria. There were no significant differences in the
serum albumin and serum creatinine levels or the estimated glom-
erularfiltrationratebetweenthetwogroups.Theadverseeffectswere
similar between the two arms, and no significance differences were
observed.
Our study indicated that rituximab treatment demonstrated ben-
efits in terms of relapse-free survival, which was consistent with
previous studies. Gulati et al. reported that rituximab treatment in
patients with SRNS or SDNS that was refractory to standard therapy
could sustain long-term relapse-free survival 30 . A study from China
reported that rituximab treatment demonstrated a 91.67% effective
rate 22 .Arecentreviewrevealedthatrituximabtreatmentreducedthe
numberofrelapsesperyear,withminimalchangeindiseaseandlittle
focal segmental glomerulosclerosis 31 . Tellier et al. reported that 4
(22%) of 18 patients with idiopathic NS who were treated with ritux-
imab experienced remission without relapse, and the remaining
patients had increased durations of remission 32 . In patients who
received one dose of rituximab (375 mg/m 2 ), 25%–40% were in sus-
tainedremissionat12–17months 33,34 .SinhaAindicatedthattherapy
with rituximab could reduce relapse rates in children with refractory
NS 35 .
NS is characterized by a large amount of proteinuria. Reducing
proteinuria is part of the treatment for NS. Kong et al. reported that
approximately 90.1% of patients receiving rituximab treatment
achieved complete or partial remission of proteinuria 36 . Another
study reported that rituximab treatment could significantly reduce
24-hourproteinuriainpatientswithNS 25 .Indeed,thecombineddata
indicated that rituximab treatment could reduce proteinuria.
However, rituximab did not significantly increase serum albumin.
This disparity might be attributed to the following causes. First, the
patients who were included for analysis had different pathological
patterns and different treatment responses to rituximab, which
might have influenced the results. For example, the pathogenetic
differences between children who are resistant ab initio and those
with delayed resistance would have resulted in different treatment
effects. The study reported by Magnasco A 26 might have included
patients with different genetic backgrounds or sensitivities to ritux-
imab and, thus, might have indicated that rituximab might not be a
good choice in children who were unresponsive to steroids and cal-
cineurin inhibitors, particularly for those unresponsive ab initio. By
contrast, some case series have reported that rituximab might have a
good effect on NS who are unresponsive to prednisone and calci-
neurin inhibitors 30,37 . Second, the administration of rituximab dif-

Hasil (Inggris) 3:

ourmeta analysisincludedthreerctsandtwocomparativecontrol
研究涉及184例。有89例患者利妥昔单抗在-
臂和95例对照组。我们的研究结果表明
thatrituximabtreatmentcouldsignificantlyimprovetherelapse自由
患者生存率与对照相比
NS治疗。此外，利妥昔单抗治疗似乎具有较高的完整
缓解率（39.62%对利妥昔单抗与控制25.45%）。
此外，利妥昔单抗治疗显著降低单纯性蛋白尿
。在
血清白蛋白和血清肌酐水平或估计的理解-
erularfiltrationratebetweenthetwogroups差异无统计学意义。theadverseeffectswere
相似的两个臂之间，无意义的差异
观察
。我们的研究表明，利妥昔单抗治疗证明本-
福利方面的无复发生存率，这与先前的研究一致
。Gulati等人。报道称，在
SRNS或SDNS，标准治疗难治性
患者利妥昔单抗治疗可以维持长期无复发生存率30。一项来自中国的研究报告称，利妥昔单抗治疗表现为91。67%有效
率22。arecentreviewrevealedthatrituximabtreatmentreducedthe
numberofrelapsesperyear，withminimalchangeindiseaseandlittle
局灶节段性肾小球硬化31。特利尔等。报道称，4
（22%）18例原发性NS患者利妥昔单抗-
经历缓解无复发治疗，其余
患者缓解持续时间增加32。患者
接受一个剂量的利妥昔单抗（375毫克/米2），25%–40%在持续
tainedremissionat12–17等。sinhaaindicatedthattherapy
利妥昔单抗可降低难治性
NS 35儿童复发率。
NS的特点是大量蛋白尿。减少蛋白尿是治疗生理盐水的一部分。香港等。报告称，约90。1%的患者接受利妥昔单抗治疗，达到完全或部分缓解蛋白尿36。另一个
研究报道，利妥昔单抗治疗能显著降低
24 hourproteinuriainpatientswithns 25。事实上，thecombineddata
表明，利妥昔单抗治疗可降低蛋白尿。
然而，利妥昔单抗并未显著提高血清白蛋白。
这种差异可能是由于以下原因。首先，对被纳入分析的患者有不同的病理学类型，对利妥昔单抗的治疗反应不同，这可能对结果有一定的影响。例如，儿童谁是耐从头算和那些具有延迟性，会导致不同的治疗效果。该研究报告由具备26可能包括
患者不同遗传背景的利妥昔单抗-
或敏感，因此，可能表明，利妥昔单抗可能不是一个好的选择
儿童反应迟钝的类固醇和卡尔-
cineurin抑制剂，特别是对那些反应迟钝从头。通过
对比，一些病例报道，利妥昔单抗可能有
效果好的NS那些对激素和降钙
神经碱剂的探讨。第二，利妥昔单抗性管理—